AtriCure, Inc. cash flow to debt ratio of 65.14% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

AtriCure, Inc.'s free cash flow has increased -529.00% from $-11.26M last year to $48.28M, signaling increasing performance

AtriCure, Inc.'s debt to equity ratio is 0.14, which means that the company's assets are healthy financed, signaling financial stability.

AtriCure, Inc.'s debt has decreased relative to shareholder equity from 0.17 last year to 0.14 today, signaling strengthened financials

AtriCure, Inc. has a net cash position, so leverage is healthy.

AtriCure, Inc.'s interest coverage ratio is 1.97, which means that the company struggles to meet interest obligations, signaling financial risk.

AtriCure, Inc.'s profit margin has increased (-119.28%) in the last year from -9.61% to 1.85%, signaling increasing performance

AtriCure, Inc.'s short-term assets of $322.52M exceed its short-term liabilities of $81.52M

AtriCure, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

AtriCure, Inc.'s return on equity of 2.14%, is lower than 15.00%, indicating bad performance

AtriCure, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

AtriCure, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

AtriCure, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

AtriCure, Inc. has a free cash flow yield of 2.28%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

AtriCure, Inc.'s yearly earnings has increased -74.39% since last year from $-44.70M to $-11.45M, signaling increasing performance

AtriCure, Inc.'s yearly revenue has increased 14.88% since last year from $465.31M to $534.53M, signaling increasing performance

ROIC 2.04% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

AtriCure, Inc.'s 3-year revenue CAGR of 17.40% is positive, indicating growing revenue over the past 3 years

AtriCure, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

AtriCure, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

AtriCure, Inc. has insufficient data to evaluate this check.

AtriCure, Inc. has an earnings yield of 0.52%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

AtriCure, Inc. is overvalued relative to its fair value price of 3.82 based on EBITDA multiple model

AtriCure, Inc. has an EV/EBITDA ratio of 125.49x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

AtriCure, Inc. is overvalued relative to its fair value price of -14.48 based on Earnings Fair Value model

AtriCure, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

AtriCure, Inc. has a price-to-book ratio of 3.91x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

AtriCure, Inc. has a price-to-sales ratio of 3.55x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue